Cagrilintide

Cagrilintide is a next-generation peptide designed to support weight management by mimicking the natural hormone amylin, which plays a critical role in regulating appetite and satiety. Often used alongside GLP-1 agonists like Semaglutide, Cagrilintide enhances feelings of fullness, reduces cravings, and supports sustainable fat loss. Its multi-pathway action makes it a promising tool for individuals seeking advanced metabolic and weight optimization strategies.

Benefits:

• Increases satiety and reduces overall calorie intake
• Enhances weight loss when combined with GLP-1 therapies
• Supports improved appetite regulation and reduced cravings
• May contribute to better blood glucose control
• Promotes sustainable, long-term fat loss and body recomposition

Dosing Cagrilintide:

• Typical Starting Dose: 0.3 mg subcutaneously once weekly
• Titration: Gradually increase to 1.2 mg weekly over 4–6 weeks based on tolerance and goals
• Maintenance Dose: 0.9 mg–1.2 mg weekly depending on individual response
• Administration: Subcutaneous injection into the abdomen, thigh, or upper arm
• Important: Titrate slowly to minimize nausea and gastrointestinal discomfort

Note: Dosing may vary based on combination therapies.

Potential Adverse Effects:

• Mild nausea, particularly during early dose escalation
• Decreased appetite (typically expected and beneficial)
• Constipation or bloating
• Rare: Injection site irritation, dizziness, mild headache
• Hypoglycemia risk is low unless combined with certain diabetic medications

Most side effects are dose-dependent and improve with proper titration.

NOTE: This is not medical advice. Peptides are intended for research purposes only.